<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">McKenna, William J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of Genetic Testing in Cardiomyopathy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-8</style></pages><abstract><style  face="normal" font="default" size="100%">Does understanding the genotype/phenotype of hypertrophic cardiomyopathy (HCM) influence management of the disease in relation to treatment, risk, and counseling? This article discusses the potential clinical value of molecular diagnosis in HCM. The most important contribution of mutation analysis is clarification of diagnosis rather than preclinical diagnosis (testing of asymptomatic carriers).</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>